Clinical Trials List
Protocol NumberDS8201-A-U303
Completed
2019-02-01 - 2023-08-04
Phase III
Terminated3
-
Trial Applicant
IQVIA RDS Taiwan Ltd.
-
Sponsor
-
Trial scale
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Ya-Ping Chen Division of Hematology & Oncology
- Kuo-Ting Lee Division of General Surgery
- Ya-Ting Hsu Division of Hematology & Oncology
- Wu-Chou Su Division of Hematology & Oncology
- Yao-Lung Kuo Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 林季宏 Division of Hematology & Oncology
- Hsin-Yu Liu Division of Ophthalmology
- 張端瑩 Division of Hematology & Oncology
- 陳怡君 Division of Hematology & Oncology
- 羅喬 Division of General Surgery
- MING-YANG WANG Division of General Surgery
- Wei-Wu Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 巫承哲 Division of General Surgery
- Sheau-Fang Yang Division of Others -
- Fu Ouyang Division of General Surgery
- Chieh-Han Chuang Division of General Surgery
- Junping Shiau Shiau Division of General Surgery
- 甘蓉瑜 Division of General Surgery
- Fang-Ming Chen Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
14 participants
-
Global
540 participants
